• SARS-CoV-2 N Protein Rewires GADD34 Immunity

  2026-09-20

  Liu et al. identify an atypical stress-granule mechanism in which SARS-CoV-2 nucleocapsid protein recruits GADD34 mRNA into N/G3BP1-positive foci, weakening IRF3-dependent interferon signaling. The work connects RNA localization, stress-granule biology, and viral immune evasion while suggesting experimental strategies for dissecting RNA–protein interactions.

• Bestatin Chemistry Dissects Jasmonate Signaling

  2026-09-19

  The reference study established bestatin as a chemical genetics probe that activates COI1-dependent jasmonate responses while remaining partly uncoupled from jasmonic acid biosynthesis. By combining transcriptional profiling, developmental assays, and bestatin-resistant Arabidopsis mutants, the authors identified a practical route to discovering previously unrecognized regulators of plant hormone signaling.

• DM-β-CD Raises Mianserin HCl Cytotoxicity

  2026-09-18

  The reference study characterized how heptakis (2,6-di-O-methyl)-β-cyclodextrin interacts with Mianserin HCl and tested whether complexation reduces cellular toxicity. Instead, the inclusion system increased toxicity in B14 cell assays, showing that improved solubility and host–guest binding do not necessarily produce a safer antidepressant formulation.

• Trelagliptin Succinate: Mechanism and Research Use

  2026-09-18

  Trelagliptin succinate, also called SYR-472 succinate, is a long-acting DPP-4 inhibitor used in diabetes mellitus research. Evidence supports incretin-related glucose regulation and an experimental AMPK/SOX-9 protective effect in IL-1β-stressed human chondrocytes.

• CX-5461: A Mechanism-First Cancer Research Guide

  2026-09-17

  CX-5461 is an RNA polymerase I inhibitor that connects rRNA transcriptional stress with DNA damage, mitotic catastrophe, autophagy, and senescence. This guide presents a mechanistic assay framework for interpreting solid tumor growth inhibition and cisplatin-response studies without mistaking a single endpoint for target engagement.

• Berberine hydrochloride Workflows for Gut-Bone Research

  2026-09-17

  Build reproducible metabolic, intestinal-barrier, and osteoimmune experiments around a well-characterized berberine hydrochloride research reagent. This guide translates tuft-cell and gut-bone findings into practical formulation, assay, comparison, and troubleshooting decisions without overextending preclinical evidence.

• Elobixibat hydrate: IBAT Research Workflows

  2026-09-16

  Build mechanistic assays around Elobixibat hydrate, a selective ileal bile acid transporter inhibitor that links bile acid redistribution with intestinal secretion, motility, and TGR5–GLP-1 signaling. This guide separates evidence-backed clinical context from practical starting conditions for constipation, colonoscopy preparation, and metabolic research.

• Elobixibat Hydrate: IBAT Mechanism and Use

  2026-09-16

  Elobixibat hydrate is a selective ileal bile acid transporter inhibitor that increases intestinal bile acid exposure and supports bowel motility. Product information describes oral use in chronic idiopathic constipation, bowel preparation prior to colonoscopy, and metabolic research involving type 2 diabetes mellitus.

• Peroxynitrite–Ca2+ Signaling in Cardiac I/R Injury

  2026-09-15

  Liu et al. define a mechanistic pathway linking hyperhomocysteinemia to cardiac microvascular endothelial necroptosis during ischemia–reperfusion. Their cell and rat studies place peroxynitrite-driven ER stress, IP3R-dependent Ca2+ transfer, mitochondrial overload, and membrane injury in a connected sequence, while pharmacological IP3R inhibition improves cardiac outcomes.

• Bortezomib (PS-341) Cancer Research Workflows

  2026-09-15

  Build reproducible Bortezomib (PS-341) experiments around reversible 20S proteasome inhibition, matched vehicle controls, and orthogonal apoptosis readouts. The workflow also positions PS-341 as a mechanistic comparator for the FOXM1-selective, autophagy-dependent strategy described in the reference study.

• Ferrostatin-1 (Fer-1) Workflow for Ferroptosis Assays

  2026-09-14

  Ferrostatin-1 (Fer-1) provides a practical rescue control for testing whether iron-dependent lipid peroxidation drives cell death. This workflow combines formulation guidance, dose-and-time optimization, orthogonal readouts, and troubleshooting for cancer, neuronal, oligodendrocyte, and ischemic injury models.

• Elobixibat Hydrate: IBAT Mechanism & Evidence

  2026-09-14

  Elobixibat hydrate is a selective ileal bile acid transporter inhibitor that increases colonic bile acid exposure and supports bowel motility. Current evidence supports its use in chronic idiopathic constipation and provides a clinical-trial framework for bowel preparation before colonoscopy, while metabolic findings remain context-dependent.

• EPZ-6438: EZH2 Inhibitor Workflow Guide

  2026-09-13

  EPZ-6438 is a selective EZH2 inhibitor for connecting PRC2 activity with H3K27me3 loss, transcriptional remodeling, and cancer-cell phenotypes. This guide translates its use into practical workflows for malignant rhabdoid tumor, EZH2-mutant lymphoma, and combination-resistance studies.

• 3-Deazaadenosine hydrochloride: Assay Logic

  2026-09-12

  Explore how 3-Deazaadenosine hydrochloride can function as a mechanistic perturbation tool for SAHH-dependent methylation research. This guide connects methyl-metabolism control with the IGF2BP1–TUBB4B–FAK liver-fibrosis model while emphasizing assay interpretation, controls, and translational limits.

• RHEB Neddylation Activates mTORC1 in Liver Tumors

  2026-09-11

  The reference study identifies RHEB as a non-cullin substrate of the UBE2F–SAG neddylation machinery and maps the functionally important modification to Lys169. By connecting this modification to RHEB lysosomal localization, GTP binding, mTORC1 activation, and liver tumorigenesis, the work provides a mechanistic link between neddylation and oncogenic nutrient signaling.

8624 records 1/575 page Next 12345 下5页 Last page